generic drugs

47. Tobacco - a nuisense created by man!

Submitted by Bhagavan P S on Tue, 01/10/2012 - 10:43
Thanks to Shiva for a good opening topic for 2012. I wish you are not a smoker or at least a ex-smoker now! Cigarette is one such product that does more harm when used in the right way! Cigarette is the only product on the market that is perhaps exempted from disclosing the contents. There are no quality parameters which you can use to cross check the quality.

EU is going to ban herbal drugs from April 2011

Submitted by sanjaypatel on Mon, 02/07/2011 - 15:04
Its really strange but its the fact that europen union is gong to ban the herbal drugs from all european union from April 2011 under the The European Directive on Traditional Herbal Medicinal Products (THMPD). In current scenario all other countries moving towards natural and herbal therapy, EU is going opposite to them. For further details please click below link

Mylan gets approval for Nisoldipine ER Tablets with 180 days exclusivity

Submitted by sanjaypatel on Wed, 02/02/2011 - 14:56
Mylan Inc.has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nisoldipine Extended-release Tablets, 8.5 mg, 17 mg, 25.5 mg and 34 mg. Earlier Mylan has developed the different strengths like 20 mg, 30 mg and 40 mg but later discontinued from the market.

Sorry i'm back now

Submitted by Pettho on Mon, 12/13/2010 - 14:02
Shalom to everyone. I first wanna apologize for replying a little late some comment that you left on my blog. Actually i just came out from the hospital. Last Tuesday Dec 7th, i was admitted to the Hospital for a Knee Surgery. As you can read on my profile that i am soccer professional and a month ago i got a knee injury. Anyhow i got discharged tonight.

One more P IV filer against INTUNIV(TM) of Shire

Submitted by sanjaypatel on Tue, 10/26/2010 - 14:42
INTUNIV(TM) is product of Shire plc and contains 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets. This product has 3 patents listed in orange book; US5854290 ("the '290 patent") titled Use of Guanfacine in the Treatment of Behavioral Disorders; US6287599 ("the '599 patent") and US6811794 ("the '794 patent") both titled Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles. The three patents expire in 2015, 2020 and 2022, respectfully.

Botox is now for the treatment of migraine

Submitted by sanjaypatel on Mon, 10/25/2010 - 14:45
USFDA has finally given the green light to Allergan for its product Botox injection (onabotulinumtoxinA) for the new indication that is prevention of headaches associated with chronic migraine in adult patients. As per the survey this new indication is going to add $ 1 billion to the existing annual sales of $1.3 billion.

Intas Pharma confirms genric supply deal with Astrazeneca

Submitted by sanjaypatel on Mon, 09/20/2010 - 14:24
After Torrent Pharmaceuticals, another Ahmedabad based pharma firm Intas Pharmaceuticals Ltd has entered into a licensing and supply agreement with UK-based drug maker Astrazeneca. Intas will supply generic, high-end oncological products manufactured at its Matoda site near Ahmedabad to Astrazeneca. Intas declined to share the financial details of the deal.

Drug marketing approval may be delinked with patent status

Submitted by sanjaypatel on Mon, 09/20/2010 - 13:48
Drug marketing approvals may be delinked from patent status Marketing approvals for generic drugs may soon get delinked from their patent status, a long-standing demand of India's pharmaceutical industry that depends heavily on the sale of generic drugs.

Troikaa Pharma's Dynapar AQ extends patent portfolio

Submitted by sanjaypatel on Wed, 09/15/2010 - 13:58
Troikaa Pharmaceuticals Ltd, an Ahmedabad-based pharmaceutical firm has been granted a patent this week for 'Dynapar AQ', a painkiller injection, in the Commonwealth of Independent States also known as the CIS block. The CIS countries include Ukraine, Kazakhastan, Belarus, Uzbekistan, Turkmenistan, Kyrgystan, Russia among others.

Bayer has received European approval for a new formulation of Levitra (vardenafil HCI)

Submitted by sanjaypatel on Sat, 09/11/2010 - 06:23
Bayer claimed that Levitra 10mg orodispersible tablet is expected to be the first ED medication available in this new and convenient formulation. Levitra 10mg orodispersible tablet is expected to allow men a discreet and convenient intake without water, dissolving on the tongue within seconds with a minty flavour.

Bedford Labs gets US FDA nod for Sumatriptan Succinate inj in pre-filled syringes

Submitted by sanjaypatel on Thu, 09/09/2010 - 15:25
Ohio based Bedford Laboratories, informed that the company has further diversified their product offerings with the addition of pre-filled syringes. FDA approval has been granted and Sumaptriptan Succinate injection, 6mg (base) / 0.5 mL pre-filled syringes are now available. This is a very important product addition to their expanding portfolio of products.

Aurobindo Pharma receives 23 pdt approvals from MCC, South Africa

Submitted by sanjaypatel on Thu, 09/09/2010 - 15:24
Aurobindo Pharma has received approvals from Medicines Control Council (MCC), South Africa for 23 registrations to manufacture and market in South Africa. With these approvals, Aurobindo has a total of 48 products representing 91 registrations approved by the MCC.

Fixed dose combinations will be reduced in india

Submitted by sanjaypatel on Mon, 09/06/2010 - 14:21
Since long the battle between pharmaceutical manufacturers and DCGI and FDA is going on for the issue of fixed dose combination of 2 or more drugs. The main issue was these fixed dose combination were marketed without any clinical trials. However the pharma companies were arguing that individual compounds are safe and effective and available in the market since long so the combinations are also safe.

Combination of Telmisartan + Amlodipine shows good results

Submitted by sanjaypatel on Mon, 09/06/2010 - 14:08
After the study, Data show that treatment with a single-pill combination of telmisartan, an angiotensin receptor blocker, (ARB) and amlodipine, a calcium channel blocker (CCB) results in significant reductions in blood pressure (BP) in patients with severe hypertension. The data, which was presented recently at 20 th Scientific Meeting of the European Society of Hypertension (ESH) in Oslo, and was discussed at a briefing in Stockholm, also demonstrate the consistently higher BP control/response rates achieved compared to treatment with telmisartan or amlodipine treatment alone